The menopause crisis, a record Dow, a tight oil market, and Trump’s $1.8 billion fund
TLDR: How last week's watch list actually landed, then the full read. The FDA quietly stripped its harshest warning off menopause hormone therapy, your cue to reopen a conversation a flawed 2002 study shut down for two decades. The Dow set a record, Nvidia blew out earnings, Google staged a comeback, and SpaceX opened its books. None of it settled the market's nerves. The reason sits underneath all of it: oil. The world has plenty of crude. The problem is slack, the cushion that keeps a supply shock off your kitchen table, and it's draining fast. That keeps inflation hot and the rate cuts everyone's banking on out of reach, which is why long rates won't behave and bonds look more worried than stocks. Two stories off the market page matter just as much. Trump pardoned roughly 1,600 January 6 defendants last year, and this week his Justice Department built a $1.776 billion fund some of them may get to tap. Call it what it is: patronage.
What resolved from Monday’s watch list
Google I/O. The flashy agent, Spark, still isn't usable. The one you can actually turn on, Daily Brief, is the quiet one.
Nvidia. Beat everything, and the stock fell anyway. The bar is now perfect, and then what.
SpaceX. The filing landed, and the mythology finally has a balance sheet.
The Fed. Warsh got the chair. Bonds answered by selling off.
Oil and Hormuz. Not America running out of gas. The buffer is what's vanishing, and fast.
The Hormone Replacement Therapy (HRT) reversal nobody sent you a memo about
If you are not familiar with the conversation around menopause in general, it’s a global health crisis in our opinion, and you don’t need to be approaching menopause to give a shit. This impacts every woman with a uterus. Here is a podcast that does an excellent deep dive into the history of HRT and the unsubstantiated claims that have long surrounded the topic: Armchair Expert with Mary Claire Haver.
Now, onto a few important developments worth your attention:
In February, the FDA approved label changes for six menopausal hormone therapy products. They removed boxed-warning language tied to cardiovascular disease, breast cancer, and probable dementia from those products. The six products cover different categories. Prometrium is progesterone. Divigel, Cenestin, and Enjuvia are systemic estrogen products. Bijuva combines estrogen and progesterone. Estring is vaginal estrogen.
A boxed warning is the agency’s strongest safety warning, and for two decades, the menopause conversation carried the shadow of that label. The agency’s own data point on why it’s suddenly taking action: in 2020, of roughly 41 million U.S. women aged 45 to 64, only about 2 million had a hormone therapy prescription.
The warnings came from the old Women’s Health Initiative. After that study, the public memory was oversimplified to ‘hormones are dangerous”. The medical conversation became almost as blunt. Too many women were told to live with hot flashes, sleep disruption, vaginal pain, urinary symptoms, brain fog, mood changes, and bone loss risk as if those were just the normal cost of aging. The FDA now says randomized studies show that women who start HRT within 10 years of menopause, generally before age 60, see reductions in all-cause mortality and bone fractures (which become more common after menopause due to estrogen’s role as a protector maintaining bone density).
Aging women have not gotten the same medical seriousness aging men have. Menopause affects roughly half the population, but for decades it was treated like a lifestyle inconvenience instead of a major health transition. Erectile dysfunction got blockbuster drugs, ads, and a mainstream treatment conversation. Menopause got fear, confusion, and a lot of “that’s just what happens.”
The cleanest part of the change is vaginal estrogen. Low-dose vaginal estrogen is local, used mainly for vaginal and urinary menopause symptoms, and has much lower whole-body absorption. Many menopause doctors have argued for years that it should not carry the same broad warning as systemic hormone therapy.
Systemic HRT is more complicated. Pills, patches, and gels circulate through the body, so the risk-benefit conversation still matters. The strongest case is usually for women who are under 60 or within 10 years of menopause and are treating real symptoms: hot flashes, night sweats, sleep disruption, vaginal symptoms, urinary symptoms, or bone loss risk. Broader claims around heart disease, cognition, Alzheimer’s, and longevity are still debated and should not be treated like settled facts.
And based on the most current research, systemic estrogen-alone therapy can still raise the risk of endometrial cancer in women who have a uterus. That is why women with a uterus are often prescribed progesterone along with estrogen.
What still needs to change is bigger than a label.
More doctors need better menopause training. More research needs to separate women by age, timing, symptoms, formulation, dose, and route instead of treating “HRT” like one giant category. And the mainstream conversation needs to stop treating women’s suffering in midlife as either vanity or vibes.
So what should you do with this information?
Do not hear “take hormones.” Hear “reopen the conversation.”
If you are in perimenopause, menopause, or the first 10 years after menopause, and you have symptoms that are affecting your sleep, sex life, mood, urinary health, or bone health, ask a more specific question than “Is HRT safe?”
Ask:
Given my age, symptoms, uterus status, family history, and risk factors, is there a form of hormone therapy that makes sense for me?
And if you want to understand it more before approaching your doctor, start with Dr. Mary Claire Haver, Dr. Jen Gunter, and Dr. Stephanie Faubion at Mayo Clinic. Then book the appointment and have a conversation with your doctor. If this isn’t a concern for you yet, talk to other women in your life: like your mom, your aunts, your mentors.
The Dow hit a record. The bond market hit the brakes.
The Dow closed at a record 50,285.66 on Thursday, helped by hopes that the U.S.-Iran peace talks might make progress. The S&P 500 and Nasdaq also rose, but less dramatically. Investors aren’t fleeing the market but they are also cautious about what happens if oil stays expensive, inflation stays sticky, and the rate cuts everyone wants don’t come.
The oil story is the simplest place to start.
The world is not out of oil but we are running out of slack. Reuters reported that cumulative supply losses now exceed 1 billion barrels and inventories are being drawn down at record speed.
Slack, or excess in the system, is what keeps a supply shock from impacting your life. When it disappears, the first signs don’t always look like empty gas stations.
That is the point behind an oil-change warning Jordi Visser gave this week. He is not saying America suddenly has no crude oil. He is saying modern cars need specific refined inputs, including synthetic lubricant base oils, and those inputs come from the same strained global petroleum system. If the wrong refineries are offline, the wrong shipping lanes are blocked, or the wrong feedstocks get scarce, your local shop may still have oil, but not necessarily the exact formulation it normally uses at the normal price.
That is how a geopolitical shock travels: it looks like a more expensive oil change, a delayed delivery, a thinner shelf at AutoZone, or a supplier quietly raising prices before consumers understand why.
The market is trying to price a world where the Strait of Hormuz stays unreliable for longer than investors expected because higher oil prices feed inflation. If inflation stays alive, the Fed has less room to cut rates. If the Fed has less room to cut rates, long-term borrowing costs stay higher. And when borrowing costs stay higher, expensive growth stocks have less room for error.
That is why Nvidia belongs in this section.
The company reported record quarterly revenue of $81.6 billion, up 85% from a year earlier. Data-center revenue hit $75.2 billion. Nvidia also added $80 billion to its share-repurchase authorization. On paper, it was the kind of quarter that should have carried the whole AI trade.
Yet the stock still fell about 1.8%.
The market isn’t rewarding “excellent.” It is asking whether excellent is already priced in.
For the last two years, every Nvidia win helped prove the AI buildout was real. Now the buildout is assumed so investors are asking harder questions: Can China revenue come through? Can margins hold? Can hyperscalers keep spending at this pace? Can the power grid handle it? Can the market keep paying premium multiples if oil and rates stay high?
The two numbers to watch right now are Brent and the 10-year Treasury yield. If oil stays high and the 10-year keeps pushing up, the market’s favorite assumptions get harder to defend: cheaper money, lower inflation, endless AI spending, and no real consequences from the war.
Trump pardoned them. Now his DOJ may pay them.
In January 2025, Trump pardoned roughly 1,600 people charged over January 6. This week, his Justice Department created a $1.776 billion “Anti-Weaponization Fund” to compensate people who claim they were targeted by a weaponized justice system.
When lawmakers asked Acting Attorney General Todd Blanche whether January 6 defendants who assaulted police officers could receive money, he would not rule it out. His answer was anybody in the country can apply.
Reuters reported that Republican pushback over the fund helped stall an ICE funding vote. AP reported that some Senate Republicans are resisting what critics see as a taxpayer-funded path to compensate January 6 rioters. CBS News reported that January 6 defendants and Trump allies are already eyeing the money.
Plainly: Trump pardoned the (read his) people charged over January 6. Now his Justice Department has built a public-money process that may let some of them seek compensation.
This is patronage.
It tells Trump’s allies that their loyalty is rewarded. It tells future loyalists something even darker: if you act for him, the state may protect you, pardon you, and even pay you.
The thing to watch next is: who ends up getting paid, denied, and whether Congress or the courts stop the fund before the money moves.
Google was supposed to lose search. Now it wants to run your day.
A year ago, many thought Google had missed AI. ChatGPT would eat search. Gemini was late. The old internet gatekeeper was finally vulnerable.
The joke was on them. Google Search revenue grew 19% last quarter, AI Overviews now reach 2.5 billion users, and the Gemini app has passed 900 million monthly active users. The thing people thought AI would break is still growing. Now Google is using that same distribution to push AI into the rest of your life.
Google already sits inside Gmail, Calendar, Drive, Docs, Sheets, Slides, YouTube, Maps, and Android. At I/O on Tuesday, it turned that position into a clearer product strategy: use AI not just to answer prompts, but to act across the places where your life already happens.
Two new consumer products to know:
Daily Brief is the practical one. Google says it is rolling out in the U.S. to Google AI Plus, Pro, and Ultra subscribers. Overnight, it pulls from your Gmail, Calendar, and Gemini chats, then delivers a prioritized morning digest with suggested next steps.
Spark is the bigger idea, but not the thing to pay for today. Google describes Gemini Spark as a 24/7 AI agent that can work across Google products, run in the background, and take action under your direction. It is meant to keep working even when your device is off, and Google says it will check with you before major actions. Spark went to trusted testers this week, with a U.S. beta for AI Ultra subscribers planned next week.
The pricing matters too. Google introduced a $100 per month AI Ultra plan and cut its top AI Ultra plan from $250 to $200. The pricing is a sign of the company trying to win market share.
Don’t overhaul your stack because of a keynote, not yet anyway. Try Daily Brief if you already have access. Wait on Spark until existing users prove it can finish multi-step work without babysitting.
SpaceX finally shows its numbers
SpaceX has spent years as a company investors could mostly experience through spectacle. Rockets landing upright. Starlink terminals in war zones. Musk talking about Mars.
The IPO filing changes that.
SpaceX is trying to raise $75 billion at a valuation near $2 trillion, a scale that would make it the largest IPO ever. And unlike most companies pitching a future this big, SpaceX has already earned the right to be taken seriously. It made reusable rockets real. It built the dominant launch business. It turned satellite internet into a working global network. Musk’s Mars timeline may sound absurd until you remember how many of his absurd ideas became real and changed the world we live in.
For those thinking about buying on IPO day, some useful information came from under the hood: Reuters reported that Starlink was the only profitable division in early 2026, while xAI drove most of SpaceX’s first-quarter capital spending. The rocket company is profitable in places. The satellite internet business is working. The AI bet is where a lot of the money is going. And the filing says Musk will retain about 85% of the voting power through a dual-class share structure. So public investors may get access to SpaceX, but they will not get much say over the direction of the business.
You are buying into the full Musk thesis: that rockets, satellites, AI, robotics, and energy are not separate bets, but one connected infrastructure stack, with the Moon as the near-term proof point and Mars still sitting at the edge of the pitch.
Yes, it is a huge swing. It may also be the kind of swing only SpaceX could credibly ask public investors to fund.
